Providence St Joseph Hospital Performs World’s First Spine Surgery Using eCential Robotics’ Open Spine Robot, with Spineart Compatible Implants

Providence St Joseph Hospital announced it has successfully performed the world’s first robotic spinal surgery using a new open spine platform by eCential Robotics to implant a Spineart medical device.

eCential Robotics, a surgical robotics company which developed the open surgical platform and Spineart, a leader in spine surgery innovation, are collaborators in a new age of open technology sharing that allows cross-functional use of implantation devices and robotic surgical platforms.
“In our relentless pursuit of innovation and excellence in patient care, we were eager to utilize the solutions provided by Spineart and eCential,” said Erick Westbroek*, M.D., Providence St Joseph spinal surgeon. “The integration of Spineart’s advanced implant system with eCential’s open robotic platform will enable us to perform minimally invasive surgeries with high predictability, reproducibility and outcomes.”
Providence St. Joseph Hospital has become the first clinical institution in the world to be equipped with the state-of-the-art robot, and the recent surgeries are the first in the United States to be used successfully in conjunction with Spineart implants.
“St. Joseph Hospital has built a strong reputation for world-class surgical care, and our patients often travel from far and wide to seek treatment and care from our stellar spine and orthopedic surgeons, who are armed with cutting-edge technology,” said Brian Helleland, chief executive of Providence St. Joseph Hospital and the Orange County/High Desert area. “These advances provide yet another sophisticated platform for our surgeons to do what they do best.” 
“We are thrilled to announce the installation of this state-of-the-art robot at St. Joseph Hospital,” said Jerome Trividic, CEO of Spineart. “We believe this advancement will greatly benefit our customers, hospitals, surgeons, and patients by enhancing surgical precision and improving patient outcomes.”
St. Joseph’s surgical cases for eCential Robotics are a first-in-human use of its unified robotic technology, as well as the start of eCential operations in the US. It also marks the introduction of cutting-edge solutions that address the evolving needs of surgeons and patients worldwide.
“We are pleased to see the adoption of our technology in the US,” Clément Vidal, CEO of eCential Robotics. “There is strong interest and momentum for our open solution because it allows surgeons to select the optimal implant system for each patient while providing financial advantages to hospitals. Our platform is described as the smartphone of surgical robots.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”